Since 2011, Terrell Herring has served as the president of Alamo Pharma Services, Inc., in Doylestown, Pennsylvania. Terrell (“Terry”) Herring dedicates a significant amount of his time to the community and formerly functioned as a trustee of Big Brothers Big Sisters of America (BBBSA). This organization provides critical mentorship and programs to at-risk youth across the nation.
BBBSA recently announced 13 grants worth a total of $560,000 to support “Bigs in Blue” programs across the nation. This new program encourages law enforcement officers to become mentors to children in their local communities. Already, the program has had an overwhelmingly positive impact in bridging the gap between youth and law enforcement in terms of trust and respect. The new grants will help expand existing Bigs in Blue programs and create new ones. In addition, seven participating cities will receive $250,000 in grants annually for the next three years from WellCare, the corporate sponsor of the new initiative. Law enforcement officers who volunteer for the program go through a vetting process and receive training before they are matched with a little. After the matching, Bigs in Blue go through the same monitoring processes of all volunteers with the organization.
0 Comments
A former CEO and director of InVentiv Health, Terrell (Terry) Herring assumed the role of president of Mission Pharmacal Company in 2010. The following year, Terrell Herring also began serving as president of Alamo Pharma Services, a recruitment and talent acquisition company specializing in the pharmaceutical and biotech sector.
In February 2017, Alamo announced a partnership with Napo Pharmaceuticals, Inc., to create a national sales team for the company's new FDA-approved drug Mytesi, which provides relief from noninfectious diarrhea in people with HIV who are on antiretroviral therapies. Napo Pharmaceuticals and its partner company, Jaguar Animal Health, Inc., estimate a potential U.S. market value of more than $100 million in annual sales for the drug, and Alamo will significantly help them reach that target. Mytesi's active pharmaceutical ingredient is crofelemer, an anti-secretory agent harvested from the rain forest. The twice-daily tablets yielded encouraging results in clinical trials with HIV-positive patients, showing a reduction in the average number of watery stools per week from 20 to less than two. |
AuthorTerrell Herring began working at Mission Pharmacal Company in 2010, bringing more than 25 years of experience in the pharmaceutical industry to his role as President of Commercial Operations. Archives
February 2018
Categories
All
|